Esophageal Diseases  >>  dexlansoprazole  >>  Phase 3
Welcome,         Profile    Billing    Logout  

12 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
dexlansoprazole / Generic mfg.
NCT00847808: Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy

Completed
3b
178
US
Dexlansoprazole MR QD, TAK-390, T-168390, TAK-390MR, Kapidex, Dexilant
Takeda
Gastroesophageal Reflux
04/10
04/10
NCT00251745: Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Completed
3
908
US
Dexlansoprazole MR, TAK-390MR, Kapidex, Dexilant, Placebo
Takeda
Gastroesophageal Reflux Disease
05/06
05/06
NCT00251758: Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Completed
3
908
US
Dexlansoprazole MR, TAK-390MR, Kapidex, Dexilant, Placebo
Takeda
Gastroesophageal Reflux Disease
05/06
05/06
NCT00255151 / 2005-001190-10: Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis

Completed
3
451
US
Dexlansoprazole MR, TAK-390MR, Dexilant, Kapidex, Placebo
Takeda
Esophagitis, Reflux, Esophagitis, Peptic
11/06
11/06
NCT00255164 / 2005-001189-15: Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis

Completed
3
451
US
Dexlansoprazole MR, TAK-390MR, Kapidex, Dexilant, Placebo
Takeda
Esophagitis, Reflux, Esophagitis, Peptic
11/06
11/06
NCT00321984: Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease

Completed
3
947
US
Dexlansoprazole MR, TAK-390MR, Kapidex, Dexilant, Placebo
Takeda
Gastroesophageal Reflux Disease
12/06
12/06
NCT00251693 / 2005-001187-31: Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

Completed
3
2038
US, Canada, Europe, RoW
Dexlansoprazole MR, TAK-390MR, Kapidex, Dexilant, Lansoprazole, Prevacid, AG-1749
Takeda
Esophagitis, Reflux, Esophagitis, Peptic
01/07
01/07
NCT00251719 / 2005-001188-70: Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

Completed
3
2054
US, Canada, Europe, RoW
Dexlansoprazole MR, TAK-390MR, Kapidex, Dexilant, Lansoprazole, Prevacid, AG-1749
Takeda
Esophagitis, Reflux, Esophagitis, Peptic
01/07
01/07
NCT00321737 / 2006-000419-90: Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis

Completed
3
445
US, Canada, Europe, RoW
Dexlansoprazole MR, TAK-390MR, Kapidex, Dexilant, Placebo
Takeda
Esophagitis, Reflux, Esophagitis, Peptic
05/07
05/07
NCT00255190: Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Completed
3
591
US
Dexlansoprazole MR, TAK-390MR, Kapidex, Dexilant
Takeda
Gastroesophageal Reflux Disease
06/08
06/08
NCT00627016: A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn

Completed
3
305
US
Dexlansoprazole, TAK-390, T-168390, TAK-390MR, Kapidex, Dexilant, Placebo
Takeda
Gastroesophageal Reflux
03/09
03/09
NCT02873702: Efficacy and Safety of Dexlansoprazole in Healing and Maintaining Healing of Erosive Esophagitis

Terminated
3
37
RoW
Dexlansoprazole, Lansoprazole, Placebo
Takeda
Erosive Esophagitis
10/17
11/17

Download Options